> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-44/
- Published: 2021-09-26T12:00:00.000Z
- Updated: 2026-09-14T17:16:08.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5141761

**Eli Lilly** has acquired **ARMO BioSciences** at a price of $50.00 per share in cash (27.5 million outstanding shares). The transaction gives Lilly promising clinical immunotherapy asset, pegilodecakin, to its oncology portfolio.

**Roche** has agreed to acquire all outstanding shares of Cambridge, MA-based **Foundation Medicine** that will bring its sequencing diagnostics platform under the Roche umbrella. In December, Foundation Medicine gained FDA approval for its sequencing diagnostics test for solid tumors that can detect cancer-causing mutations in 324 genes.

**Astellas** has paid $102.5 million for **Universal Cells**, a biotech that the company says is developing a platform technology intended to do away with the testing needed to ensure cell therapy products aren’t rejected by a patient’s immune system. It uses recombinant adeno-associated viral vectors to edit the genomes of pluripotent stem cells by switching off human leukocyte antigen expression in a way that does not cause “off-target” DNA cutting — which could lead to unintended effects. The resulting universal donor cells won’t require donor matching or immune-suppressing therapy and don’t stimulate rejection, according to the biotech.